1. Home
  2. ALT vs JRI Comparison

ALT vs JRI Comparison

Compare ALT & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • JRI
  • Stock Information
  • Founded
  • ALT 1997
  • JRI 2012
  • Country
  • ALT United States
  • JRI United States
  • Employees
  • ALT N/A
  • JRI N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • JRI Finance Companies
  • Sector
  • ALT Health Care
  • JRI Finance
  • Exchange
  • ALT Nasdaq
  • JRI Nasdaq
  • Market Cap
  • ALT 292.0M
  • JRI 367.7M
  • IPO Year
  • ALT N/A
  • JRI N/A
  • Fundamental
  • Price
  • ALT $3.83
  • JRI $13.57
  • Analyst Decision
  • ALT Strong Buy
  • JRI
  • Analyst Count
  • ALT 6
  • JRI 0
  • Target Price
  • ALT $17.40
  • JRI N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • JRI 68.0K
  • Earning Date
  • ALT 08-12-2025
  • JRI 01-01-0001
  • Dividend Yield
  • ALT N/A
  • JRI 9.38%
  • EPS Growth
  • ALT N/A
  • JRI N/A
  • EPS
  • ALT N/A
  • JRI N/A
  • Revenue
  • ALT $20,000.00
  • JRI N/A
  • Revenue This Year
  • ALT N/A
  • JRI N/A
  • Revenue Next Year
  • ALT $761,880.20
  • JRI N/A
  • P/E Ratio
  • ALT N/A
  • JRI N/A
  • Revenue Growth
  • ALT N/A
  • JRI N/A
  • 52 Week Low
  • ALT $2.90
  • JRI $9.70
  • 52 Week High
  • ALT $11.16
  • JRI $12.12
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • JRI 65.61
  • Support Level
  • ALT $3.35
  • JRI $13.27
  • Resistance Level
  • ALT $3.66
  • JRI $13.48
  • Average True Range (ATR)
  • ALT 0.19
  • JRI 0.10
  • MACD
  • ALT 0.07
  • JRI 0.01
  • Stochastic Oscillator
  • ALT 86.18
  • JRI 96.87

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest

Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.

Share on Social Networks: